共 266 条
[1]
Wolff ACHM(2013)Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update J Clin Oncol 31 3997-4013
[2]
Hicks DG(2011)HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies Expert Rev Anticancer Ther 11 263-275
[3]
Dowsett M(2009)Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors Breast Cancer Res 11 R31-602
[4]
McShane LM(2009)Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004 Breast J 15 593-1205
[5]
Allison KH(2017)11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial Lancet 389 1195-7819
[6]
Allred DC(2014)Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2–positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N983 J Clin Oncol 23 7811-3799
[7]
Bartlett JM(2012)Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2–positive breast cancer J Clin Oncol 30 3792-587
[8]
Bilous M(2016)Long term cardiac safety analysis of NCCTG N9831 (alliance) adjuvant trastuzumab trial J Clin Oncol 34 581-1283
[9]
Fitzgibbons P(2011)Adjuvant trastuzumab in HER2-positive breast cancer N Engl J Med 365 1273-5692
[10]
Hanna W(2009)Fluorouacil, epirubicin and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer trial J Clin Oncol 27 5685-6134